HAMSA THERAPEUTICS
Live / Allowed — Notice of allowance issued (as of 02 Sept 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 11 Dec 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98897961
- Mark type
- Stylized text
- Filed
- 11 Dec 2024
- Published for opposition
- 08 Jul 2025
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: therapeutic pharmaceuticals for the prevention and treatment of muscle, metabolic, cardiovascular, renal, and respiratory diseases; pharmaceutical preparations for the prevention and treatment of muscle, metabolic, cardiovascular, renal, and respiratory diseases; biological preparations for the prevention and treatment of muscle, metabolic, cardiovascular, renal, and respiratory diseases; biological therapies for the prevention and treatment of muscle, metabolic, cardiovascular, renal, and respiratory diseases
- Class 042 — Scientific and technological services: scientific research for medical purposes in the field of muscle, metabolic, cardiovascular, renal, and respiratory diseases; research and development of therapeutics for the treatment of muscle, metabolic, cardiovascular, renal, and respiratory diseases; research and development in the field of small molecule drug discovery for muscle, metabolic, cardiovascular, renal, and respiratory diseases; medical and scientific research in the field of muscle, metabolic, cardiovascular, renal, and respiratory diseases; medical and scientific research in the field of pharmaceuticals for muscle, metabolic, cardiovascular, renal, and respiratory diseases; pharmaceutical products development in the field of muscle, metabolic, cardiovascular, renal, and respiratory diseases; drug discovery services in the field of muscle, metabolic, cardiovascular, renal, and respiratory diseases; pharmaceutical research and development services in the field of muscle, metabolic, cardiovascular, renal, and respiratory diseases; research and development in the field of precision medicine for muscle, metabolic, cardiovascular, renal, and respiratory diseases
Owner
- Hamsa Therapeutics, Inc., San Francisco, CA, US
- Hamsa Therapeutics, Inc., San Francisco, CA, US
Prosecution history
- 02 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Jul 2025 — PUBLISHED FOR OPPOSITION
- 02 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Jun 2025 — EXAMINER'S AMENDMENT ENTERED
- 05 Jun 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 05 Jun 2025 — EXAMINERS AMENDMENT E-MAILED
- 05 Jun 2025 — EXAMINERS AMENDMENT -WRITTEN
- 30 May 2025 — ASSIGNED TO EXAMINER
- 27 Apr 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 11 Dec 2024 — NEW APPLICATION ENTERED